Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Apr 30, 2010
Trial Information
Current as of July 16, 2025
Completed
Keywords
ClinConnect Summary
The aim of this study was to show consistency with the EMPHASIS-HF trial (NCT00232180), which was defined as a HR of the primary endpoint of below 1.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Japanese chronic systolic heart failure patients with LVEF =\<30% by echocardiography and NYHA II or more
- • Patients who receive standard therapy (Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blocker or diuretic)
- Exclusion Criteria:
- • Patients with a myocardial infarction, stroke, cardiac surgery or percutaneous coronary intervention within 30 days prior to randomization.
- • Patients with serum potassium \>5.0 mmol/L or eGFR \<30 ml/min/1.73 m2.
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sapporo, Hokkaido, Japan
Fujisawa, Kanagawa, Japan
Osaka, , Japan
Fukushima, , Japan
Komatsushima, Tokushima, Japan
Osaka, , Japan
Tsu, Mie, Japan
Kumamoto, , Japan
Yonago Shi, Tottori, Japan
Nishinomiya, Hyogo, Japan
Seto, Aichi, Japan
Bunkyo Ku, Tokyo, Japan
Shinjuku Ku, Tokyo, Japan
Fukuoka, , Japan
Kashihara, Nara, Japan
Chuo, Yamanashi, Japan
Ube, Yamaguchi, Japan
Asahi, Chiba, Japan
Nagoya, Aichi, Japan
Chiba Shi, Chiba Ken, Japan
Inzai, Chiba, Japan
Matuyama Shi, Ehime, Japan
Fukuoka Shi, Fukuoka Ken, Japan
Iizuka Shi, Fukuoka Ken, Japan
Kurume Shi, Fukuoka Ken, Japan
Koriyama, Fukushima, Japan
Ogaki, Gifu, Japan
Hakodate Shi, Hokkai Do, Japan
Hakodate, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Himeji, Hyogo, Japan
Himeji, Hyogo, Japan
Toride Shi, Ibaraki, Japan
Kannonji, Kagawa, Japan
Sagamihara, Kanagawa, Japan
Sendai Shi, Miyagi Ken, Japan
Suita Shi, Osaka Fu, Japan
Kishiwada, Osaka, Japan
Sakai Shi, Osaka, Japan
Yodogawa Ku, Osaka, Japan
Kasukabe Shi, Saitama, Japan
Saitama Shi, Saitama, Japan
Kusatsu Shi, Shiga Ken, Japan
Hamamatsu Shi, Shizuoka, Japan
Shimotsuke Shi, Tochigi, Japan
Chiyoda Ku, Tokyo, Japan
Ube City, Yamaguchi, Japan
Gifu, , Japan
Kumamoto, , Japan
Okayama, , Japan
Osaka, , Japan
Takasaki Shi, , Japan
Toyama, , Japan
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials